Monoclonal Antibody

Overview

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
T CELL RECEPTOR DEPLETION IN STEM CELL TRANSPLANT
Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

B-Cell Maturation Antigen (BCMA)

B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.

CD38

CD38 is a protein that may be found on the surface of many immune system cells (including multiple myeloma cells). This protein may be used as a way for treatments to target (or find) myeloma cells.

Programmed Death Receptor-1 (PD-1)

PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.

Resources

There are no resources, links or videos to display for this tag.